Company news

Share this article:

Merck has agreed to purchase San Diego-based NovaCardia, a privately held clinical-stage pharmaceutical company focused on cardiovascular diseases, for $350 million plus the amount of cash on hand at the time of closing. Merck will pay for NovaCardia in Merck stock, to be valued based on the average closing stock price on the five days prior to closing of the deal. NovaCardia's lead product candidate, KW-3902, is being studied in late-stage clinical trials in patients with acute congestive heart failure. In March, NovaCardia filed with the Securities and Exchange Commission to raise up to $86.3 million in an initial public offering. 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.